Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jun 9;9(6):626.
doi: 10.3390/vaccines9060626.

Vaccination in PADs

Cinzia Milito  1 , Valentina Soccodato  1 , Giulia Collalti  1 , Alison Lanciarotta  2   3 , Ilaria Bertozzi  2   3 , Marcello Rattazzi  2   3 , Riccardo Scarpa  2   3 , Francesco Cinetto  2   3
Affiliations
Review

Vaccination in PADs

Cinzia Milito et al. Vaccines (Basel). .

Abstract

Primary antibody deficiencies (PADs) are the most common primary immunodeficiencies (PIDs). They can be divided into the following groups, depending on their immunological features: agammaglobulinemia; common variable immunodeficiency (CVID) isotype; hyper IgM isotype; light chain or functional deficiencies with normal B cell count; specific antibody deficiency with normal Ig concentrations and normal numbers of B cells and transient hypogammaglobulinemia of infancy. The role of vaccination in PADs is recognized as therapeutic, diagnostic and prognostic and may be used in patients with residual B-cell function to provide humoral immunity to specific infective agents. According to their content and mechanisms, vaccines are grouped as live attenuated, inactivated (conjugated, polysaccharide), mRNA or replication-deficient vector vaccines. Vaccination may be unsafe or less effective when using certain vaccines and in specific types of immunodeficiency. Inactivated vaccines can be administered in PAD patients even if they could not generate a protective response; live attenuated vaccines are not recommended in major antibody deficiencies. From December 2020, European Medicines Agency (EMA) approved vaccines against COVID-19 infection: according to ESID advises, those vaccinations are recommended in patients with PADs. No specific data are available on safety and efficacy in PAD patients.

Keywords: antibody deficiency; immunization; immunodeficiency; vaccination recommendations.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Eibl M.M., Wolf H.M. Vaccination in patients with primary immune deficiency, secondary immune deficiency and autoimmunity with immune regulatory abnormalities. Immunotherapy. 2015;7:1273–1292. doi: 10.2217/IMT.15.74. - DOI - PubMed
    1. Tangye S.G., Al-Herz W., Bousfiha A., Chatila T., Cunningham-Rundles C., Etzioni A., Franco J.L., Holland S.M., Klein C., Morio T., et al. 2019 Update on the Classification from the International Union of Immunological Societies Expert Committee. J. Clin. Immunol. 2020;40:24–64. doi: 10.1007/s10875-019-00737-x. Erratum in: J. Clin. Immunol.2020, 40, 24–64. - DOI - PMC - PubMed
    1. Durandy A., Kracker S., Fischer A. Primary antibody deficiencies. Nat. Rev. Immunol. 2013;13:519–533. doi: 10.1038/nri3466. - DOI - PubMed
    1. Mieves J.F., Wittke K., Freitag H., Volk H.D., Scheibenbogen C., Hanitsch L.G. Influenza Vaccination in Patients with Common Variable Immunodeficiency (CVID) Curr. Allergy Asthma. Rep. 2017;17:78. doi: 10.1007/s11882-017-0749-3. - DOI - PubMed
    1. Quinti I., Soresina A., Spadaro G., Martino S., Donnanno S., Agostini C., Claudio P., Franco D., Pesce A.M., Borghese F., et al. Italian Primary Immunodeficiency Network. Long-term follow-up and outcome of a large cohort of patients with common variable immunodeficiency. J. Clin. Immunol. 2007;27:308–316. doi: 10.1007/s10875-007-9075-1. - DOI - PubMed